| INTRODUCTION
Hepatitis C virus (HCV) remains a global burden worldwide and the leading cause of liver cirrhosis with its associated complications including hepatic decompensation and hepatocellular carcinoma (HCC), 1, 2 The worldwide seropositivity is around 115 million (1.6%), with actual viremic patients at around 71 million (1%) (range 62-79 million). 1, 3 Egypt is one of the highest endemic seropositive areas worldwide (>5%) with respect to the adult population. 4 The implementation of the combined PEGylated interferon and ribavirin regimen (PEG-IFN/ RBV) in the standard of care for chronic HCV-infected Egyptian patients of genotype 4 was associated with a limited sustained virological response (SVR), reaching a maximum of 60%. 5 The launch of the National Treatment Programme of chronic HCV with direct-acting antiviral drugs (DAAs) improved the SVR to higher levels using different DAAs; SVR reached 96% in sofosbuvir (SOF)/PEG-IFN/RBV, 6 (78%-98%) in SOF/ribavirin (SOF/RBV), 7 in SOF/simeprevir (SOF/SIM) (94%-100%) 5, [8] [9] [10] in SOF/daclatasvir (SOF/DCV) reached (95.1%), 11 in SOF/ledipasvir (SOF/LED) reached (87%-97%) 12 and in paritaprevir/ ombitasvir/ritonavir/ribavirin (PTV/OBV/r/RBV) (94%-97%). 13 The list of adverse effects secondary to PEG-INF/RBV combination is long, in addition to the limitation of this regimen in decompensated cirrhosis and other patients. The use of DAAs in all age groups and even in patients with decompensated liver cirrhosis as well as those with renal diseases has increased the incidence of adverse side effects development. The adverse effects of DAAs have not been thoroughly discussed. Identification of the adverse effects in the different DAA regimens, particularly in those with advanced liver cirrhosis will help in improving the selection of patients who will benefit from each regimen and decrease the incidence of decompensation and risk of complications. Thus, the aim of this study was to evaluate the adverse effects associated with different DDA regimens in Egyptian patients.
| PATIENTS AND METHODS

| Study cohort
This study was conducted in compliance with the Helsinki Declara- with DAAs and were included in this study. Figure 1 shows the flow diagram of the treatment regimens, illustrating patients who developed adverse effects according to each regimen and treatment response. Death occurred in 85 patients (3.4%) during treatment, due to various causes (mostly hepatic decompensation); three of them died due to diabetic comas, some reported deaths of unknown aetiologies. Forty-six patients reached SVR24 and three patients were relapsers, while 39 patients died before SVR24. SVR24 was not reported in n = 879/2475 patients with side effects. Patients were further classified according to the presence (n = 1689) and absence (n = 786) of serious adverse effects. 
| Efficacy of DAAs in patients with adverse events
A total of 1642/2475 patients with side effects reached SVR24. The overall SVR24 was detected in n = 1450/1642 patients (88%), 43 of those died, mostly due to hepatic decompensation. Relapse was observed in n = 192/1642 patients (12%), and three patients of those died secondary to hepatic decompensation. SVR24 data were lost in 879/2475 patients, of those 39 patients died before reaching SVR24. SVR24 in SOF/RBV was 89%, SOF/SIM was 87%, SOF/DCV was 90%, SOF/DCV/RBV was 86%. of the developed side effects, (0.4%) of the treated patients with hyperbilirubinemia accounted for (24%, P = 0.058), one patient had angiomatous oedema and two patients had photosensitivity. Patients on SOF/DCV had the lowest side effects, haematological and hepatobiliary were (0.04%) and (0.04%) of the treated patients. One patient developed leukaemia (Table 2 ). Only 5 patients on PVT/OBV/r/RBV regimen developed side effects, one had anaemia, one had hyperbilirubinemia and 3 patients had non-specific side effects.
| Management of treatment due to serious adverse events
Patients on SOF/RBV had the highest incidence of serious side effects of all regimens (n = 1227, 73%, P < 0.001). Secondary to serious side effects, treatment stopped in (50%, P = 0.003) of patients, continued in 37% and in 13% of patients, the dose of RBV decreased or stopped with increasing the duration of treatment to 24 weeks. In SOF/DCV/ RBV treatment stopped in (73%, P < 0.001), continued in (25%) and RBV dose change (dose decrease or RBV stoppage) was in 2% of patients. Patients on SOF/SIM and SOF/DCV stopped treatment in 50% and continued in 50%. Anaemia was the most common serious side effect (n = 731/1689, 43%) with SOF/RBV the most common causing regimen (80%, P < 0.001). Patients with no serious side effects to DAA treatment continued treatment until W12 and W24 in comparison to those with anaemia and hyperbilirubinemia (log rank <0.001; Figure 3 ). Treatment discontinuation with anaemia was more common than with hyperbilirubinemia (log rank = 0.005).
3.5 | Adverse events were more common in cirrhotic patients
The incidence of serious side effects was higher in patients with liver cirrhosis than those without (1409/1999, 71%; log rank = 0.045; Figure 4) . Similarly, the incidence of mortality was higher in patients with liver cirrhosis than those without (79/1999, 4%, log rank = 0.025).
3.6 | Mortality-related DAA regimens Patients who received SOF/DCV/RBV had 17% pre-treatment thrombocytopenia. DAA treatment discontinuation was highest at week 4 (37%, P < 0.001).
| Factors predicting serious adverse effects
To predict factors associated with development of serious side effects during DAA treatment, demographic, laboratory, and clinical factors before treatment were evaluated; multivariate analysis revealed that male gender, lower haemoglobin, platelets and albumin, The baseline characteristics of the study cohort according the different treatment regimens. Data are given as M AE SD. Patients on SOF/RBV regimen had the highest cirrhosis rate, lower platelets and albumin and higher bilirubin at baseline. DAA, direct antiviral drugs; SOF/RBV, sofosbuvir/ribavirin; SOF/DCV, sofosbuvir/daclatasvir; SOF/DCV/RBV, sofosbuvir/daclatasvir/ribavirin; BMI, body mass index; TLC, total leucocytic count; ANC, absolute neutrophilic count; INR, international normalization ratio; AST, aspartate transaminase; ALT, alanine transaminase; US, ultrasonographic; LSM, liver stiffness measurement; TE, transient elastography, PHG, portal hypertensive gastropathy.
higher bilirubin, higher Child-Pugh score, presence of liver cirrhosis before treatment were factors associated with serious side effects development during DAA treatment (Table 3) . Regarding the regimens, lower platelets and the presence of liver cirrhosis were factors predicting serious side effects in SOF/DCV, while the presence of cirrhosis was the only factor associated with serious side effects in the SOF/DCV/RBV regimen. Lower platelet count, higher bilirubin and the presence of liver cirrhosis were the factors associated with serious side effects in the SOF/RBV regimen, while only lower platelet count was the only factor associated with side effects development in the SOF/SIM regimen (Table 4) . 
| DISCUSSION
To our knowledge, this is the first study with such a large cohort of chronic HCV-infected patients treated with DAAs who reported associated adverse effects and related death. This study revealed that interferon-free regimens are associated with minimal side effects, which are mostly non-serious. The most common side effects were haematological complications, with anaemia being the dominant one, particularly with respect to the SOF/RBV regimen.
The serious haematological adverse effects were managed with haematopoietic agents, treatment discontinuation or reduction in RBV dose with prolongation of treatment duration. The SOF/RBV regimen showed the highest rate of side effects, with anaemia being the prominent one. The SOF/SIM regimen was associated with hyperbilirubinemia; however, this was not significant and did not require treatment discontinuation or a change in drug dosage.
DCV-containing regimens showed the lowest side effects among all regimens. This study also showed that death was highest in the SOF/RBV regimen and pre-treatment thrombocytopenia and higher
Child score were the dominant pre-treatment associated pathologies. In this study, HCC was reported in 33 patients, and this was mostly with the SOF/RBV regimen; however, this was not significant. Serious adverse effects as well as death were prominent with liver cirrhosis under the interferon-free regimens irrespective of the regimen.
The initial approval of DAAs by the Egyptian Council Committee of Viral Hepatitis had dramatically improved the SVR rate in Egyptian chronic HCV-infected patients, from 60% to almost 100% in some studies. 5, 8, 10 Our study showed that SVR24 reached 88% in those who developed side effects. Although the majority of the study cohort were cirrhotic patients (81%), side effects development was minimal (1.7%), in comparison to other studies, the entire cohort of which were cirrhotic patients and reported 24% side effects. 16 Serious side effects that led to reduction in the RBV dose and prolongation of the treatment duration or even treatment discontinuation, were observed in only (1.1%) of cases. Anaemia was the most common serious side effect, and was mostly associated with the SOF/ RBV regimen. The rate of serious side effects was lower in comparison to that of the Guard-C study, which reported 5.9% serious side effects, while the incidence of anaemia in our study was higher (29.5% vs 25%). 17 Interestingly, our multivariate analysis confirmed that pre-treatment HB (<12.6 g/dL) and lower platelets (124 9 10 3 / lL) were associated with post-treatment serious side effects development, as previously mentioned. 18 Our large cohort also revealed that the pre-treatment higher Child-Pugh score represented in lower albumin <35 g/dL and higher bilirubin >1.2 lmol/dL were also factors associated with post-treatment serious side effects development. Lower albumin was also described by Maan et al and Foster et al as factors associated with post-treatment serious side effects development. 16, 17 The second common serious side effect was hyperbilirubinemia, which was not significant and was only prominent in the SOF/RBV regimen. Non-specific side effects such as fatigue, headache and abdominal discomfort were the most commonly reported in all regimens, which is line with all previously published data. 5, 7, 8, 10, 16, 19, 20 Death was reported in only 0.06% of all treated patients, and was mainly associated with the SOF/RBV regimen. Death was in most of the cases secondary to hepatic decompensation. Three The hematological, hepatic causes and non-specific side effects among the different DAA regimens, anemia was highest in SOF/RBV while hepatobiliary complications were most common in SOF/SIM regimen. Cardiovascular and blood sugar disturbance as well as diabetic coma were reported only with SOF/RBV, while photosensitivity cases were reported in SOF/DCV and SOF/SIM regimens. DAA, direct antiviral drugs; SOF/RBV, sofosbuvir/ribavirin; SOF/DCV, sofosbuvir/daclatasvir; SOF/DCV/RBV, sofosbuvir/daclatasvir/ribavirin; SOF/SIM, sofosbuvir/simeprevir; HCC, hepatocellular carcinoma; PVT, portal vein thrombosis. Hepatocellular carcinoma was also reported in 0.02% of all treated patients, and most cases were reported in the SOF/RBV regimen. This incidence is, however, lower when compared to other studies. 21, 22 The incidence of HCC on this regimen can be explained by the associated liver cirrhosis in 89% of patients, which is line with previous published data, 23 and 22% were Child-Pugh B, which may favour disease progression and the presence of regenerative nodules before the start of treatment. It is to be noted, that the presence of cirrhosis was associated with increased death rate and was also the common factor detected in all regimens associated with serious side effects development.
The incidence of serious side effects, death and HCC development was highest in the SOF/RBV regimen. This can be explained by the fact that this regimen was the first approved regimen for DAAs, and all patients treated with this regimen were the most sick (lower platelets and higher Child-Pugh score B). On the other hand, SOF/DCV showed the lowest incidence of side effects in comparison to the other regimens.
This study was conducted on a large cohort of Egyptian patients, more than 90% of which are infected with genotype 4. 7 Egypt is one of the countries with the highest prevalence with HCV infection, and the urgency to treat chronic HCV patients is associated with reduction in prevalence, which already started to appear, with 29% reduction in prevalence in 2015. 4 This study has several limitations; although we are reporting the adverse effects of several regimens, many of these regimens may no longer be used in several countries (eg SOF/RBV combination is no longer recommended in the European and American guidelines). Moreover, SIM is also rarely in use today, not due to efficacy but because of economic reasons. We must highlight that SIM is still used in many regions including Egypt. Another point to highlight is that these data were excluded from the database which were reported by the treating physicians. There may be an underreporting of adverse effects because there was no soft data verification by independent physicians; however, this is also accepted in large cohort studies. In conclusion, the use of PEG-IFN/RBV combination was limited due to eligibility, tolerability and treatment efficacy (40%-69%). 24, 25 The use of interferon-free regimens increased the SVR rate and improved the tolerability and eligibility of treatment. The use of interferon-free regimens is safe and tolerable, with a higher cure rate in patients with 
Comparison between patients with and without cirrhosis as regard the incidence of death. The percentage of patients with liver cirrhosis had a higher incidence of death than those without liver cirrhosis (log rank = 0.025). W, week.
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T A B L E 4
Multivariate analysis of serious side effects development according to the drug regimens SOF/DCV SOF/DCV/RBV SOF/RBV SOF/SIM P-value Odds ratio (95% CI)
P-value
Odds ratio (95% CI)
Odds ratio (95% CI) This table revealed that in the multivariate analysis; lower platelets, the presence of cirrhosis was associated factors with SE in the SOF/RBV regimen, while in SOF/DCV/RBV; the presence of cirrhosis was the associated factor predicting serious side effects. In SOF/RBV; lower platelets, higher bilirubin and the presence of cirrhosis were the factors associated with serious side effects development. In SOF/SIM regimen; lower platelet count was the only factor associated with serious side effects. SOF/DCV, sofosbuvir/daclatasvir; SOF/DCV/RBV, sofosbuvir/daclatasvir/ribavirin; SOF/RBV, sofosbuvir/ribavirin; SOF/SIM, sofosbuvir/simeprevir; INR, international normalisation ratio; OR, odds ratio. 
L I N K E D C O N T E N T
This article is linked to Papanikolaou and Papadimitropoulos paper.
To view this article visit https://doi.org/10.1111/apt.14580.
